Despite these therapeutic alterations, the authors reported that gliomas recurred in their xenograft model displaying lower expression of IL13Rα2, signifying the critical need that CAR-T cells promote immune responses against multiple tumor antigens. Here, IL13RA2 is linked to neoplasm.